AI in Oncology Market

AI in Oncology Market (Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Ovarian Cancer, and Others; Application: Diagnosis, Treatment Selection, Drug Discovery, and patient Management and Care) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

AI in Oncology Market Outlook 2034

  • The global industry was valued at US$ 1.3 Bn in 2023
  • It is expected to grow at a CAGR of 16.8% from 2024 to 2034 and reach US$ 7.7 Bn by the end of 2034

Analyst Viewpoint

The AI in oncology market’s growth is due to rise in prevalence of cancer worldwide. AI uses advanced algorithms that can grasp large volumes of data related to route them toward precise diagnosis of cancer, predict disease progression, and give proper prognosis.

Such algorithms have the ability of outperforming human brains by identification of subtle patterns as well as correlations in genetic data, medical imaging, and the other types of patient information.

The key players in AI in oncology industry are devising AI-powered pathology panels for spatial analysis of tumor microenvironment.

They are also exploring the usage of generative AI in single-cell research for stem cell therapies. Continuous innovation is thus one of the AI in oncology market trends, which is making greater strides in the oncology vertical.

Market Introduction

Need for precise diagnoses of cancer coupled with customized treatment recommendations are prompting the healthcare personnel to opt for AI. Moreover, AI can speedily analyze complex datasets, which helps oncologists in detection of tumors and deciding the course of treatment.

The clinicians are empowered by AI to make well-informed decisions regarding treatment for cancer. AI-based clinical decision support systems recommend optimized regimens of therapy by learning from outcomes of a large pool of patients.

These recommendations take the patient’s genomic profile of tumor, responses to initial lines of therapy, and various other factors into account. AI in the form of decision-making tool is thus aiding oncologists choose the right drugs, sequencing of therapies, and drug combinations.

However, AI models are bound to incorrectly conclude forged correlation between outcome labels and data features, resulting in ungeneralizable, misleading, and/or biased conclusions. This factor may restrain the AI in oncology market growth during the forecast period.

Attribute Detail
Market Drivers
  • Rise in Incidence of Cancer with Speedy Adoption of AI by Developing Economies
  • AI Progression

Increase in Incidence of Cancer with Speedy Adoption of AI by Developing Economies Propelling Artificial Intelligence in Cancer Care

As per the WHO, there were 20 million new cancer cases registered worldwide, with 9.7 million individuals succumbing to it. It further states that 20% of the people contract cancer in their lifetime.

Moreover, lung cancer is responsible for 1.8 million fatalities, followed by colorectal cancer. Breast cancer and belly cancer are more prevalent amongst the women.

Increase in the body mass index, lack of physical activity, and higher consumption of tobacco are responsible for higher incidence of cancer worldwide. Adopting AI for detecting cancer will help in starting with the treatment earlier than the normal course. Besides, AI detection has a higher precision quotient as compared to detection by humans.

The developing economies are also witnessing an expansion in healthcare infrastructure along with adoption of AI.

For instance, in July 2021, the Centre for Fourth Industrial Revolution of the World Economic Forum India announced launching the Fourth Industrial Revolution for Sustainable Transformation (FIRST) of the Cancer Care project in order to emphasize advanced technologies such as AI, blockchain, and IoT to deliver easily accessible, affordable, and high-quality cancer care in India.

Need to combat cancer in a faster manner coupled with the developing countries adopting AI is thus driving the AI in oncology market opportunities

Advancements in AI driving Computational Oncology

Chemotherapy has been used to destroy the rapidly moving cancer cells since the last several years. Integrating AI with chemotherapy helps healthcare personnel in developing the patients’ personalized digital profile, through which the dose can be personalized.

In June 2022, the National University of Singapore (NUS) announced that it had developed CURATE.AI solution, which uses clinical data such as the drug’s dosage, medications, and presence of biomarkers for customizing the patient’s digital profile. This, in turn, offers personalized chemotherapy dosage recommendations.

Additionally, AI models are employed in order to predict chemotherapy responses as well as cancer prognosis.

For instance, in September 2022, the European Society for Medical Oncology (ESMO) Congress 2022 presented a study, in which it highlighted the probability of response to cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC).

AI is increasingly used in breast cancer’s radiographic imaging to facilitate early diagnosis and treatment. In January 2021, the U.S. FDA approved Visage Breast Density medical device and Imagio Breast Imaging System.

Need for speedy detection and treatment of cancer is thus expanding the AI in oncology market size.

Regional Analysis of AI Adoption and Implementation in Oncology Practices

Attribute Detail
Leading Region North America

As per the latest AI in oncology market analysis, North America held the largest share of AI-driven oncology landscape in 2023 and the status quo is expected to remain unchanged during the forecast period. This is attributed to the U.S. emphasizing advanced AI solutions for diagnosing and treating cancer.

Research states that AI curtails MRI scanning time, thereby resulting in cost-cutting and higher patient outcomes. Along these lines, the American Society of Clinical Oncology has stated that there were close to 5% reductions in treatment costs pertaining to medical oncology in the U.S. in 2022 due to usage of AI.

The key players are also strategically collaborating to expedite the invention of therapeutics using AI.

For instance, in November 2021, Sanofi-Aventis U.S. LLC announced a strategic investment of US$ 180 million in Owkin, Inc. to expand its oncology portfolio regarding multiple myeloma, breast cancer, and lung cancer for optimizing clinical trial design and detecting predictive biomarkers for treatment outcomes with the help of AI.

AI is shaping Canadian healthcare as well. The Canadian Cancer Society 9CCS) supports AI applications by funding the research related to early detection of cancer. For instance, in December 2023, the CCS provided funds to four research teams for innovating in early cancer detection, prevention, and care using AI.

Analysis of AI in Oncology Market Manufacturers

The companies specializing in AI-driven oncology solutions are engaged in new product launch to establish a strong foothold in AI-assisted cancer diagnosis.

For instance, in September 2021, Owkin, Inc. announced development of deep-learning model capable of predicting health outcomes regarding hepatocellular carcinoma.

This model was an outcome of the company’s collaboration with researchers from Cleveland Clinic. Furthermore, in August 2022, Medtronic plc introduced GI GeniusTM intelligent endoscopy module all over India.

Powered by AI, it helps the healthcare personnel in detecting colorectal cancer through improved visualization at the time of colonoscopy.

Paige.AI, Tempus, Ibex Medical Analytics, PathAI, Proscia Inc., DeepMind, SOPHiA GENETICS, Enlitic, Prognos Health, and Inspirata, Inc. are some of the key participants covered in the AI in oncology market report.

These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments in AI in Oncology Market

  • In March 2023, Qritive announced that it had come up with an AI-based tool called QAi Prostate to diagnose prostate cancer.
  • In December 2022, MedCognetics, Inc. announced that the U.S. FDA had given 510(k) clearance to its AI-enabled software called QmTRIAGE for breast cancer screening.

Global AI in Oncology Market Snapshot

Attribute Detail
Market Size in 2023 US$ 1.3 Bn
Market Forecast (Value) in 2034 US$ 7.7 Bn
Growth Rate (CAGR) 16.8%
Forecast Period 2024-2034
Historical Data Available for 2020-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2023)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Cancer Type
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Ovarian Cancer
    • Others
  • Application
    • Diagnosis
    • Treatment Selection
    • Drug Discovery
    • Patient Management and Care
  • End-user
    • Hospitals & Clinics
    • Cancer Hospitals
    • Research Institutes
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Paige.AI
  • Tempus
  • Ibex Medical Analytics
  • PathAI
  • Proscia Inc.
  • DeepMind
  • SOPHiA GENETICS
  • Enlitic
  • Prognos Health
  • Inspirata, Inc.
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global AI in oncology market in 2023?

It was valued at US$ 1.3 Bn in 2023

How is the AI in oncology business expected to grow during the forecast period?

It is projected to advance at a CAGR of 16.8% from 2024 to 2034

What are the key factors driving the demand for AI in oncology?

Growing prevalence of cancer with speedy adoption of AI by developing economies and advancements in AI

Which AI in oncology end-user segment held the largest share in 2023?

Cancer hospitals segment accounted for the largest share in 2023

Which region dominated the global AI in oncology landscape in 2023?

North America was the dominant region in 2023

Who are the key AI in oncology manufacturers?

Paige.AI, Tempus, Ibex Medical Analytics, PathAI, Proscia Inc., DeepMind, SOPHiA GENETICS, Enlitic, Prognos Health, and Inspirata, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: AI in Oncology Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. AI in Oncology Market Analysis and Forecast, 2020-2034

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Product /Brand Analysis

    5.3. Key Mergers & Acquisitions

    5.4. COVID-19 Pandemic Impact on Industry

6. Global AI in Oncology Market Analysis and Forecast, by Cancer Type

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Cancer Type, 2020-2034

        6.3.1. Lung Cancer

        6.3.2. Breast Cancer

        6.3.3. Colorectal Cancer

        6.3.4. Ovarian Cancer

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Cancer Type

7. Global AI in Oncology Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Application, 2020-2034

        7.3.1. Diagnosis

        7.3.2. Treatment Selection

        7.3.3. Drug Discovery

        7.3.4. Patient Management and Care

    7.4. Market Attractiveness Analysis, by Application

8. Global AI in Oncology Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by End-user, 2020-2034

        8.3.1. Hospitals & Clinics

        8.3.2. Cancer Hospitals

        8.3.3. Research Institutes

    8.4. Market Attractiveness Analysis, by End-user

9. Global AI in Oncology Market Analysis and Forecast, by Region

    9.1. Introduction

    9.2. Key Findings/Developments

    9.3. Market Value Forecast, by Region, 2020-2034

        9.3.1. North America

        9.3.2. Europe

        9.3.3. Asia Pacific

        9.3.4. Latin America

        9.3.5. Middle East & Africa

    9.4. Market Attractiveness Analysis, by Region

10. North America AI in Oncology Market Analysis and Forecast

    10.1. Introduction

    10.2. Key Findings

    10.3. Market Value Forecast, by Cancer Type, 2020-2034

        10.3.1. Lung Cancer

        10.3.2. Breast Cancer

        10.3.3. Colorectal Cancer

        10.3.4. Ovarian Cancer

        10.3.5. Others

    10.4. Market Value Forecast, by Application, 2020-2034

        10.4.1. Diagnosis

        10.4.2. Treatment Selection

        10.4.3. Drug Discovery

        10.4.4. Patient Management and Care

    10.5. Market Value Forecast, by End-user, 2020-2034

        10.5.1. Hospitals & Clinics

        10.5.2. Cancer Hospitals

        10.5.3. Research Institutes

    10.6. Market Value Forecast, by Country, 2020-2034

        10.6.1. U.S.

        10.6.2. Canada

    10.7. Market Attractiveness Analysis

        10.7.1. By Cancer Type

        10.7.2. By Application

        10.7.3. By End-user

        10.7.4. By Country

11. Europe AI in Oncology Market Analysis and Forecast

    11.1. Introduction

    11.2. Key Findings

    11.3. Market Value Forecast, by Cancer Type, 2020-2034

        11.3.1. Lung Cancer

        11.3.2. Breast Cancer

        11.3.3. Colorectal Cancer

        11.3.4. Ovarian Cancer

        11.3.5. Others

    11.4. Market Value Forecast, by Application, 2020-2034

        11.4.1. Diagnosis

        11.4.2. Treatment Selection

        11.4.3. Drug Discovery

        11.4.4. Patient Management and Care

    11.5. Market Value Forecast, by End-user, 2020-2034

        11.5.1. Hospitals & Clinics

        11.5.2. Cancer Hospitals

        11.5.3. Research Institutes

    11.6. Market Value Forecast, by Country/Sub-region, 2020-2034

        11.6.1. Germany

        11.6.2. U.K.

        11.6.3. France

        11.6.4. Italy

        11.6.5. Spain

        11.6.6. Rest of Europe

    11.7. Market Attractiveness Analysis

        11.7.1. By Cancer Type

        11.7.2. By Application

        11.7.3. By End-user

        11.7.4. By Country/Sub-region

12. Asia Pacific AI in Oncology Market Analysis and Forecast

    12.1. Introduction

    12.2. Key Findings

    12.3. Market Value Forecast, by Cancer Type, 2020-2034

        12.3.1. Lung Cancer

        12.3.2. Breast Cancer

        12.3.3. Colorectal Cancer

        12.3.4. Ovarian Cancer

        12.3.5. Others

    12.4. Market Value Forecast, by Application, 2020-2034

        12.4.1. Diagnosis

        12.4.2. Treatment Selection

        12.4.3. Drug Discovery

        12.4.4. Patient Management and Care

    12.5. Market Value Forecast, by End-user, 2020-2034

        12.5.1. Hospitals & Clinics

        12.5.2. Cancer Hospitals

        12.5.3. Research Institutes

    12.6. Market Value Forecast, by Country/Sub-region, 2020-2034

        12.6.1. China

        12.6.2. Japan

        12.6.3. India

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Market Attractiveness Analysis

        12.7.1. By Cancer Type

        12.7.2. By Application

        12.7.3. By End-user

        12.7.4. By Country/Sub-region

13. Latin America AI in Oncology Market Analysis and Forecast

    13.1. Introduction

    13.2. Key Findings

    13.3. Market Value Forecast, by Cancer Type, 2020-2034

        13.3.1. Lung Cancer

        13.3.2. Breast Cancer

        13.3.3. Colorectal Cancer

        13.3.4. Ovarian Cancer

        13.3.5. Others

    13.4. Market Value Forecast, by Application, 2020-2034

        13.4.1. Diagnosis

        13.4.2. Treatment Selection

        13.4.3. Drug Discovery

        13.4.4. Patient Management and Care

    13.5. Market Value Forecast, by End-user, 2020-2034

        13.5.1. Hospitals & Clinics

        13.5.2. Cancer Hospitals

        13.5.3. Research Institutes

    13.6. Market Value Forecast, by Country/Sub-region, 2020-2034

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Market Attractiveness Analysis

        13.7.1. By Cancer Type

        13.7.2. By Application

        13.7.3. By End-user

        13.7.4. By Country/Sub-region

14. Middle East & Africa AI in Oncology Market Analysis and Forecast

    14.1. Introduction

    14.2. Key Findings

    14.3. Market Value Forecast, by Cancer Type, 2020-2034

        14.3.1. Lung Cancer

        14.3.2. Breast Cancer

        14.3.3. Colorectal Cancer

        14.3.4. Ovarian Cancer

        14.3.5. Others

    14.4. Market Value Forecast, by Application, 2020-2034

        14.4.1. Diagnosis

        14.4.2. Treatment Selection

        14.4.3. Drug Discovery

        14.4.4. Patient Management and Care

    14.5. Market Value Forecast, by End-user, 2020-2034

        14.5.1. Hospitals & Clinics

        14.5.2. Cancer Hospitals

        14.5.3. Research Institutes

    14.6. Market Value Forecast, by Country/Sub-region, 2020-2034

        14.6.1. GCC Countries

        14.6.2. South Africa

        14.6.3. Rest of Middle East & Africa

    14.7. Market Attractiveness Analysis

        14.7.1. By Cancer Type

        14.7.2. By Application

        14.7.3. By End-user

        14.7.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

    15.2. Market Share Analysis, by Company (2023)

    15.3. Company Profiles

        15.3.1. Paige.AI

            15.3.1.1. Company Overview

            15.3.1.2. Product Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. Tempus

            15.3.2.1. Company Overview

            15.3.2.2. Product Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. Ibex Medical Analytics

            15.3.3.1. Company Overview

            15.3.3.2. Product Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. PathAI

            15.3.4.1. Company Overview

            15.3.4.2. Product Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Proscia Inc.

            15.3.5.1. Company Overview

            15.3.5.2. Product Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. DeepMind

            15.3.6.1. Company Overview

            15.3.6.2. Product Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. SOPHiA GENETICS

            15.3.7.1. Company Overview

            15.3.7.2. Product Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. Enlitic

            15.3.8.1. Company Overview

            15.3.8.2. Product Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Prognos Health

            15.3.9.1. Company Overview

            15.3.9.2. Product Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

        15.3.10. Inspirata, Inc.

            15.3.10.1. Company Overview

            15.3.10.2. Product Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Financial Overview

            15.3.10.5. Strategic Overview

List of Tables

Table 01: Global AI in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2020-2034

Table 02: Global AI in Oncology Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 03: Global AI in Oncology Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 04: Global AI in Oncology Market Size (US$ Mn) Forecast, by Region, 2020-2034

Table 05: North America AI in Oncology Market Size (US$ Mn) Forecast, by Country, 2020-2034

Table 06: North America AI in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2020-2034

Table 07: North America AI in Oncology Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 08: North America AI in Oncology Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 09: Europe AI in Oncology Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 10: Europe AI in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2020-2034

Table 11: Europe AI in Oncology Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 12: Europe AI in Oncology Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 13: Asia Pacific AI in Oncology Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 14: Asia Pacific AI in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2020-2034

Table 15: Asia Pacific AI in Oncology Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 16: Asia Pacific AI in Oncology Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 17: Latin America AI in Oncology Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 18: Latin America AI in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2020-2034

Table 19: Latin America AI in Oncology Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 20: Latin America AI in Oncology Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 21: Middle East & Africa AI in Oncology Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Middle East & Africa AI in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2020-2034

Table 23: Middle East & Africa AI in Oncology Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 24: Middle East & Africa AI in Oncology Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

Figure 01: Global AI in Oncology Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global AI in Oncology Market Revenue (US$ Mn), by Cancer Type, 2023

Figure 03: Global AI in Oncology Market Value Share, by Cancer Type, 2023

Figure 04: Global AI in Oncology Market Revenue (US$ Mn), by Application, 2023

Figure 05: Global AI in Oncology Market Value Share, by Application, 2023

Figure 06: Global AI in Oncology Market Revenue (US$ Mn), by End-user, 2023

Figure 07: Global AI in Oncology Market Value Share, by End-user, 2023

Figure 08: Global AI in Oncology Market Value Share, by Region, 2023

Figure 09: Global AI in Oncology Market Value (US$ Mn) Forecast, 2020-2034

Figure 10: Global AI in Oncology Market Value Share Analysis, by Cancer Type, 2023 and 2034

Figure 11: Global AI in Oncology Market Attractiveness Analysis, by Region, 2024-2034

Figure 12: Global AI in Oncology Market Value Share Analysis, by Application, 2023 and 2034

Figure 13: Global AI in Oncology Market Attractiveness Analysis, by Application, 2024-2034

Figure 14: AI in Oncology Market Value Share Analysis, by End-user, 2023 and 2034

Figure 15: Global AI in Oncology Market Attractiveness Analysis, by End-user, 2024-2034

Figure 16: Global AI in Oncology Market Value Share Analysis, by Region, 2023 and 2034

Figure 17: Global AI in Oncology Market Attractiveness Analysis, by Region, 2024-2034

Figure 18: North America AI in Oncology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 19: North America AI in Oncology Market Attractiveness Analysis, by Country, 2024-2034

Figure 20: North America AI in Oncology Market Value Share Analysis, by Country, 2023 and 2034

Figure 21: North America AI in Oncology Market Value Share Analysis, by Cancer Type, 2023 and 2034

Figure 22: North America AI in Oncology Market Value Share Analysis, by Application, 2023 and 2034

Figure 23: North America AI in Oncology Market Value Share Analysis, by End-user, 2023 and 2034

Figure 24: North America AI in Oncology Market Attractiveness Analysis, by Region, 2024-2034

Figure 25: North America AI in Oncology Market Attractiveness Analysis, by Application, 2024-2034

Figure 26: North America AI in Oncology Market Attractiveness Analysis, by End-user, 2024-2034

Figure 27: Europe AI in Oncology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 28: Europe AI in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 29: Europe AI in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 30: Europe AI in Oncology Market Value Share Analysis, by Cancer Type, 2023 and 2034

Figure 31: Europe AI in Oncology Market Value Share Analysis, by Application, 2023 and 2034

Figure 32: Europe AI in Oncology Market Value Share Analysis, by End-user, 2023 and 2034

Figure 33: Europe AI in Oncology Market Attractiveness Analysis, by Region, 2024-2034

Figure 34: Europe AI in Oncology Market Attractiveness Analysis, by Application, 2024-2034

Figure 35: Europe AI in Oncology Market Attractiveness Analysis, by End-user, 2024-2034

Figure 36: Asia Pacific AI in Oncology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 37: Asia Pacific AI in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 38: Asia Pacific AI in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 39: Asia Pacific AI in Oncology Market Value Share Analysis, by Cancer Type, 2023 and 2034

Figure 40: Asia Pacific AI in Oncology Market Value Share Analysis, by Application, 2023 and 2034

Figure 41: Asia Pacific AI in Oncology Market Value Share Analysis, by End-user, 2023 and 2034

Figure 42: Asia Pacific AI in Oncology Market Attractiveness Analysis, by Region, 2024-2034

Figure 43: Asia Pacific AI in Oncology Market Attractiveness Analysis, by Application, 2024-2034

Figure 44: Asia Pacific AI in Oncology Market Attractiveness Analysis, by End-user, 2024-2034

Figure 45: Latin America AI in Oncology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 46: Latin America AI in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 47: Latin America AI in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 48: Latin America AI in Oncology Market Value Share Analysis, by Cancer Type, 2023 and 2034

Figure 49: Latin America AI in Oncology Market Value Share Analysis, by Application, 2023 and 2034

Figure 50: Latin America AI in Oncology Market Value Share Analysis, by End-user, 2023 and 2034

Figure 51: Latin America AI in Oncology Market Attractiveness Analysis, by Region, 2024-2034

Figure 52: Latin America AI in Oncology Market Attractiveness Analysis, by Application, 2024-2034

Figure 53: Latin America AI in Oncology Market Attractiveness Analysis, by End-user, 2024-2034

Figure 54: Middle East & Africa AI in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 55: Middle East & Africa AI in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 56: Middle East & Africa AI in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 57: Middle East & Africa AI in Oncology Market Value Share Analysis, by Cancer Type, 2023 and 2034

Figure 58: Middle East & Africa AI in Oncology Market Value Share Analysis, by Application, 2023 and 2034

Figure 59: Middle East & Africa AI in Oncology Market Value Share Analysis, by End-user, 2023 and 2034

Figure 60: Middle East & Africa AI in Oncology Market Attractiveness Analysis, by Region, 2024-2034

Figure 61: Middle East & Africa AI in Oncology Market Attractiveness Analysis, by Application, 2024-2034

Figure 62: Middle East & Africa AI in Oncology Market Attractiveness Analysis, by End-user, 2024-2034

Copyright © Transparency Market Research, Inc. All Rights reserved